Verde Servicos Internacionais S.A. Boosts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Verde Servicos Internacionais S.A. boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 22.5% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,359 shares of the medical research company's stock after purchasing an additional 3,001 shares during the quarter. Thermo Fisher Scientific comprises about 4.6% of Verde Servicos Internacionais S.A.'s portfolio, making the stock its 11th biggest position. Verde Servicos Internacionais S.A.'s holdings in Thermo Fisher Scientific were worth $8,140,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Bernard Wealth Management Corp. purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $25,000. FPC Investment Advisory Inc. acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $28,000. Pillar Financial Advisors LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $29,000. Ameriflex Group Inc. acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $30,000. Finally, Noble Wealth Management PBC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $35,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

NYSE:TMO traded up $2.38 during trading hours on Monday, hitting $400.26. 2,485,958 shares of the stock were exchanged, compared to its average volume of 1,944,901. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The firm's fifty day moving average price is $411.66 and its 200 day moving average price is $486.42. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The company has a market cap of $151.09 billion, a P/E ratio of 23.48, a P/E/G ratio of 2.10 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same period in the previous year, the business earned $5.11 EPS. Thermo Fisher Scientific's quarterly revenue was up .2% on a year-over-year basis. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.43%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research reports. Stifel Nicolaus lowered their price target on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Argus decreased their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Evercore ISI decreased their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. Finally, Robert W. Baird decreased their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $605.30.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.